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Abstract 
Introduction: Shortness of breath is a common presenting symptom to the emergency 
department (ED) that can arise from a myriad of possible diagnoses. Asthma is one of the 
major causes.  
Objective: To describe the demographic features, clinical characteristics, management and 
outcomes of adults with an emergency department (ED) diagnosis of asthma who presented 
to an ED in the Asia Pacific region with a principal symptom of dyspnea.  
Methods: Planned sub-study of patients with an ED diagnosis of asthma identified in the Asia, 
Australia and New Zealand Dyspnoea in Emergency Departments (AANZDEM) study. 
AANZDEM was a prospective cohort study conducted in 46 EDs in Australia, New Zealand, 
Singapore, Hong Kong and Malaysia over three 72-hour periods in May, August and October 
2014. Primary outcomes were patient epidemiology, clinical features, treatment and 
outcomes (hospital length of stay (LOS) and mortality).  
Results: Of the 3,044 patients with dyspnea, 387 (12.7%) had an ED diagnosis of asthma. The 
median age was 45 years, 60.1% were female, 16.1% were active or recent smokers, and 30.4% 
arrived by ambulance. Inhaled bronchodilator therapy was initiated in 88.1% of patients and 
66.9% received both inhaled bronchodilators and systemic corticosteroids. After treatment in 
the ED, 65.4% were discharged. No death was reported.  
Conclusion: Asthma is common among patients presenting with a principal symptom of 
dyspnea in the ED of the Asia Pacific region. There was suboptimal adherence to 
international guidelines on investigations and treatments of acute asthma exacerbations 
presenting an opportunity to improve efficiency of care. 
Keywords: Asthma; epidemiology; emergency services, hospital; dyspnea 
Introduction 
Shortness of breath is a common presenting symptom to the emergency department 
(ED) that can arise from a myriad of possible diagnoses.1 Major etiological groups are 
cardiac and respiratory disease; among the latter asthma is one of the major causes.   
The World Health Organization estimates that over 235 million people suffer from 
asthma globally. There is large variability in the prevalence of asthma among countries 
worldwide; the highest being over 20% reported in Australia.3,4 Morbidity, mortality and the 
number of disability-adjusted life years lost due to asthma are substantial, particularly in 
lower income nations.5,6 The incidence of asthma exacerbations varies with seasons, 
environmental conditions and air pollutants.7-9 Frequent attendances to the ED by asthmatic 
patients have been associated with higher mortality.10,11   
National and international guidelines recommend a number of treatments to optimize 
outcomes.12-14 These include inhaled bronchodilators, systemic corticosteroids and targeted 
oxygen therapy.  There is limited information on the epidemiology of asthma in the Asia 
Pacific region and about compliance with guideline recommended therapies. 
The objective of this planned sub-study is to describe the demographics, clinical 
characteristics, treatment and patient outcomes of the cohort of patients who attended the ED 
in the Asia Pacific region with a primary symptom of dyspnea, and have a subsequent ED 
diagnosis of asthma.  
Materials and Methods 
The methodology of this study has been published previously.15 Briefly, the Asia, 
Australia and New Zealand Dyspnoea in Emergency Departments (AANZDEM) study is a 
prospective, descriptive cohort study conducted at three time points in 46 EDs in Australia, 
New Zealand, Singapore, Hong Kong and Malaysia of consecutive adult patients presenting 
to the ED with dyspnea as a main symptom. Data were collected over three 72-hour periods 
(13-16 May 2014, 12-15 August 2014 and 14-17 October 2014), which corresponded to the 
seasons of autumn, winter and spring in Australasia. Variables collected included 
demographics, comorbidities, mode of arrival, usual medications, pre-hospital treatment, 
initial assessment, ED investigations, treatment in the ED, ED diagnosis, disposition from the 
ED, in-hospital outcome and final hospital diagnosis. 
This planned sub-study includes patients in the AANZDEM study with an ED 
diagnosis of asthma. The primary outcomes of interest are the epidemiology, investigations 
ordered, treatments given and overall outcomes of these patients. Secondary outcomes consist 
of geographical variations of the primary outcomes and adherence to international guidelines 
on asthma management. Guidelines for the initial assessment of severity of acute asthma 
exacerbations in adults include evaluation of symptoms, vital signs, measurement of peak 
expiratory flow rate, and indications for blood gas and chest radiograph. Guidelines for 
treatment of acute asthma encompasses indications for the provision of supplemental oxygen, 
steroid therapy, beta2-agonist bronchodilators, ipratropium bromide, other forms of 
adjunctive therapy such as intravenous magnesium sulfate and prescription of antibiotics. 
Analysis was largely by descriptive statistics. Comparisons of proportions and 
measures of associations were done using the Chi-square or Fisher’s exact test, where 
appropriate. Non-parametric data were compared using the Mann-Whitney U test. Data 
analyses were performed with IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., 
Armonk, NY) and Analyse-it for Microsoft Excel, Version 2.20 (Analyse-it Software, Ltd., 
Leeds, UK). This analysis used data which was collected for studies about patients presenting 
to ED with dyspnea. Hence, a priori sample size calculations were not necessary. There may 
have been situations where the same patient presented more than once and these were not de-
duplicated. However, given the large sample sizes of the groups, this matter would be 
expected to have minimal impact on the results presented or the outcomes of the analyses 
performed. Reporting of results complies with the STROBE guidelines.16 It should be noted 
that only specific statistical tests (and hence P-values) were performed and reported, in order 
to avoid inflating Type 1 error. Human research ethics approvals were obtained for all sites 
according to local requirements. Most jurisdictions did not require patient consent for data 
collection. Some sites in Queensland required patient consent so that part of the data is not 
consecutive.  
Results 
Characteristics of Study Subjects 
Forty-six EDs contributed data on 3,044 patients with dyspnea as a presenting 
symptom. Thirty-three sites were in Australia, 4 in New Zealand, 4 in Hong Kong, 3 in 
Singapore and 2 in Malaysia. In 2014, the study sites had a combined annual ED census of 
2,886,178 patients. (See Acknowledgements for full list) 
Three hundred eighty-seven patients had an ED diagnosis of asthma (12.7%; 95% 
confidence interval (CI) 11.6 to 14.0%). Asthma cases contributed to 0.64% (387/60,059) of 
all ED attendances in the study periods. There was a higher incidence of asthma 
exacerbations among dyspneic patients in the EDs of Asian countries (171/1,086, 15.7%; 95% 
CI 13.7 to 18.1%) compared to Australia and New Zealand (216/1,958, 11.0%; 95% CI 9.7 to 
12.5%). 
Over 75% of patients were younger than 60 years (Table 1). There was a greater 
proportion of female patients with asthma in the EDs of Australia and New Zealand (ANZ) 
compared to South East Asia (SEA) (65.3 vs. 53.2%). The overall smoking prevalence was 
16.1%, again a much higher preponderance in ANZ compared to SEA (22.1 vs. 8.8%). Over 
90% of patients were previously diagnosed with asthma and 6% had a concomitant history of 
chronic obstructive pulmonary disease. Just under one-third (30.4%) arrived to the ED by 
ambulance; many more in ANZ than in SEA (37.3 vs. 21.7%). 
Medications 
Common pre-existing prescribed asthma medications are also described in Table 1 
and included: inhaled beta-sympathomimetics (74.9%), inhaled corticosteroids (46.0%), 
inhaled anticholinergics (14.7%) and oral corticosteroids (13.5%). There were more patients 
who were on inhaled anticholinergics (16.4 vs. 8.2%), inhaled corticosteroids (52.3 vs. 
38.0%), and oral corticosteroids (17.4 vs. 8.8%) in ANZ versus SEA. 
Clinical features 
Clinical features including physical examination findings are shown in Table 2. The 
majority of patients experienced between 1 and 4 days of shortness of breath before 
presenting to the ED. A small proportion (6.1%) had documented fever. There were 18.7% 
who had more severe symptoms, at best being able to only speak in phrases. Over 10% 
experienced severe tachypnea (respiratory rate ≥30 breaths per minute). More than 80% were 
found to have wheeze or rhonchi during examination. 
Investigations 
Chest radiographs were obtained in 70.4% of patients and 23.5% had blood gas 
analysis (Table 2).  
Treatment 
More than 70% did not receive any form of initial oxygen therapy in the ED (Table 3). 
Only 1 patient received non-invasive ventilation and none required endotracheal intubation. 
Over 88% received inhaled bronchodilator therapy and a lower proportion (69.7%) received 
systemic corticosteroids. Two-thirds of patients received both inhaled bronchodilators and 
systemic corticosteroids. More patients were prescribed antibiotics for their asthma 
exacerbation in ANZ compared to SEA (30.5 vs. 14.0%). 
Outcomes 
Almost two-thirds were discharged from the ED, including those who were managed 
in an ED observation unit (Table 3). Eleven (2.8%) patients required admission to the 
intensive care unit and there were no deaths reported in our cohort. Among those who 
required admission to the hospital wards, the median length of stay was 4 days (interquartile 
range 3-6 days). Of those patients admitted to hospital with asthma, asthma was confirmed as 
the final primary diagnosis in 84% with lower respiratory tract infection (9%) and chronic 
obstructive pulmonary disease (7%) being the alternative primary diagnoses.  
Discussion 
Our study shows that asthma is a relatively common diagnosis encountered in adult 
patients presenting with dyspnea to the ED in the Asia Pacific region, accounting for a higher 
proportion of cases in SEA compared to ANZ. We also found that compliance with guideline 
recommended investigations and treatments were suboptimal, from high utilization of chest 
radiographs and blood gas analyses, and increased proportion of inhaled ipratropium bromide 
administration and prescription of antibiotics, respectively. The results of this study could be 
a useful baseline reference for which future ED studies on asthma in the region could be 
based upon after education and promulgation of management guidelines and 
recommendations.12-14 
Over the last 25 years, the epidemiology of asthma exacerbations has changed to one 
of decline in hospitalization rates postulated to be due to increased use of asthma control 
medications, lower tendency for clinicians to admit patients and administrative incentives in 
certain countries to reduce hospital admission.17 However, the disposition of patients 
presenting to the ED in our study is somewhat dissimilar to those previously published in 
North America.18 The proportion of patients admitted to the hospital ward was much higher 
in our cohort (31.5% vs. 7.0%).18 We surmise that the reasons could include higher severity 
of asthma exacerbations in the region. Our rationale for this is the high proportion of patients 
who arrived to the ED by ambulance (30.4%) (Table 1); the frequency of signs suggestive of 
severe disease [difficulty speaking (18.7%) and high respiratory rate (10.9%)] (Table 2); and 
the prolonged median length of stay of 4 days for admitted patients (Table 3). Another 
explanation could be how the different populations use the ED. In Australasia there is ready 
access to primary health care that is affordable. Patients with less severe disease may have 
sought care there rather than the ED.  
The Global Initiative for Asthma12, Australian Asthma Handbook13, and British 
Thoracic Society14 provide guidelines for the management of asthma in acute care settings 
such as the ED. The guidelines include assessment, treatment, review of response and 
discharge planning of asthma exacerbations. Supplemental controlled low flow oxygen 
therapy is recommended to maintain saturation at 93-95%. The majority of patients in our 
cohort (70.8%) did not receive any supplemental oxygen and only a small proportion 
received untitrated supplemental oxygen via face mask (11.9%) and non-rebreather mask 
(1.8%). We were unable to determine whether the target oxygen saturations were met due to 
lack of data collected after initiation of oxygen therapy. 
Inhaled short-acting beta2-agonists and systemic corticosteroids are both mainstays of 
management for acute asthma exacerbations. Furthermore, there is strong evidence that 
systemic corticosteroids hasten the resolution of exacerbations and prevent relapses.19 In spite 
of this, a less than optimal 66.8% of patients received both forms of therapy in our study, 
suggesting room for improvement in efficiency of asthma care with regard to compliance to 
guidelines. 
Slightly over half (55.8%) of patients with asthma exacerbations in this study received 
inhaled anticholinergic therapy during their ED visit. Current guidelines by the Expert Panel 
of the National Asthma Education and Prevention Program recommend inhaled ipratropium 
be used for patients with severe exacerbations in the ED.20 We were unable to collect on 
structured severity assessment as different sites used different methods but if the admission 
rate of approximately 30% is taken as a proxy for more severe disease, it would appear that 
there was a disproportionately higher use of inhaled anticholinergics for the milder forms of 
asthma exacerbations in our cohort. 
Chest radiographs and blood gas measurements are not routinely recommended for 
adults with asthma exacerbations unless patients are not responding to initial therapy or are 
deteriorating.12,14 In our study, 70.4% of patients had a chest radiograph done. Previous 
studies reported only about 2% abnormal findings from chest radiographs among acute 
asthmatics in the ED.21,22 Similarly, 23.5% of patients had blood gas analysis but only 2.8% 
were eventually admitted to the intensive care unit. Reasons for the overuse of chest 
radiographs is unclear but may represent habit or a lack of awareness of the evidence and 
guideline recommendations. We reported data on blood gas analysis but did not differentiate 
between arterial and venous analyses. It is possible that clinicians used a venous blood gas 
analysis to screen for hypercarbia in patients where there was clinical concern of severe 
disease.23 
Many factors can trigger an asthma exacerbation. Most respiratory infections that 
trigger the exacerbation are viral in origin. Hence, routine use of empiric antibiotic therapy is 
not recommended.12,14, 24,25 Despite this, there was a high proportion (23.2%) of antibiotic 
usage in our study even though symptoms and signs of bacterial infection were lacking. 
Inappropriate use of antibiotics has driven the rapid increase in antibiotic resistance, and 
compounded by the dearth of new antibiotics in the pipeline, a post-antibiotic era is 
looming.26 
While lack of knowledge may be a contributor to failures to comply with guideline-
recommended investigation and treatment, it is more likely that the major reason is human 
error with contributing factors such as time constraints in ED, distraction and competing 
patient priorities as several patients are being processed by a doctor at any given time, 
imperfect memory, and cognitive overload. High staff turnover makes it difficult to ensure all 
staff are educated in clinical rationale for investigation and treatment, and guideline 
recommendations for all conditions encountered in the ED. One approach suggested to 
address deficits in care provided includes the introduction of an asthma proforma or checklist. 
An alternative approach would be the use of clinical informatics systems such as computer-
assisted decision support, which has been proven to improve patient safety and has been 
recommended by the US Agency for Healthcare Research and Quality.27 This can range from 
simple reminder systems to monitor-based color-coded guideline compliance visual alerts.
Our study has several limitations that should be considered when interpreting our 
results. First, the results may not be generalizable to other regions outside of South East Asia 
and Australasia as health care access and affordability, particularly to the ED, may differ. 
Second, asthma as a diagnosis was based on the treating ED clinician’s judgment. Although 
potentially subject to error in part related to incomplete information and investigations, this 
represents the ‘real world’ practice in EDs. Determination of patients who required guideline 
recommendations in the management of their acute asthma exacerbations were not 
individually detailed, which could have blunted the ascertainment of compliance to 
guidelines. Third, the severities of asthma exacerbations were not explicitly measured. 
Helpful information on asthma phenotype through information on history of chronicity, 
differentiation between short- and long-acting bronchodilator use, utilization of combination 
treatment of inhaled corticosteroids and long-acting bronchodilators, and frequency of 
exacerbations were not collected. It would have been useful to have had information on other 
investigations and treatment modalities, such as peak flow measurements or spirometry but 
these are inconsistently performed in ED.28 We did not have data on intravenous 
administration of magnesium sulfate to better assess compliance to international guidelines 
for patients with severe asthma.  
Conclusions 
In conclusion, this study on patients with asthma provides a unique understanding of 
regional variation in demographics, investigations and treatment in a cohort of patients from 
EDs in the Asia Pacific region. There was seemingly suboptimal adherence to international 
guidelines on investigations and treatments, which alerts us to an opportunity to improve 
efficiency of care. 
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Table 1. Patient Characteristics 
Variable 
Total population 
(N=387) 
Missing 
data 
ANZ 
(n=216) 
SEA 
(n=171) 
Age (years), median (IQR) 45 (31-60) 1 (SEA) 44 (31-59) 48 (29-60) 
Age group, No. (%; 95% CI) 
18-40 years 159 (41.1; 36.2 to 46.2) 1 (SEA) 91 (42.1; 35.5 to 49.0) 68 (39.8; 32.5 to 47.6) 
41-60 years 136 (35.1; 30.4 to 40.2) 76 (35.2; 28.9 to 42.0) 60 (35.1; 28.1 to 42.8) 
61-75 years 55 (14.2; 11.0 to 18.2) 31 (14.4; 10.1 to 19.9) 24 (14.0; 9.4 to 20.4) 
>75 years 36 (9.3; 6.7 to 12.8) 18 (8.3; 5.2 to 13.1) 18 (10.5; 6.5 to 16.4) 
Female gender, No. (%; 95% CI) 232 (60.1; 55.0 to 65.0) 1 (SEA) 141 (65.3; 58.5 to 71.5) 91 (53.5; 45.8 to 61.2) 
Co-morbidities, No. (%; 95% CI) 
Previous diagnosis asthma 351 (90.9; 87.5 to 93.5) 1 (ANZ) 195 (90.7; 85.8 to 94.1) 156 (91.2; 85.7 to 94.8) 
Active or recent smoker 62 (16.1; 12.7 to 20.3) 3 (ANZ) 47 (22.1; 16.8 to 28.4) 15 (8.8; 5.2 to 14.3) 
Chronic obstructive pulmonary 
disease 
23 (6.0; 3.9 to 9.0) 3 (ANZ) 16 (7.5; 4.5 to 12.1) 7 (4.1; 1.8 to 8.6) 
Cardiac failure 8 (2.1; 1.0 to 4.2) 3 (ANZ) 5 (2.3; 0.9 to 5.7) 3 (1.8; 0.5 to 5.4) 
Diabetes mellitus 46 (12.0; 9.0 to 15.8) 3 (ANZ) 27 (12.7; 8.7 to 18.1) 19 (11.1; 6.7 to 17.0) 
Dyslipidemia 61 (15.9; 12.5 to 20.0) 3 (ANZ) 29 (13.6; 9.5 to 19.1) 32 (18.7; 13.3 to 25.5) 
Hypertension 92 (24.0; 19.8 to 28.6) 3 (ANZ) 48 (22.5; 17.2 to 28.9) 44 (25.7; 19.5 to 33.1) 
Ischemic heart disease 24 (6.3; 4.1 to 9.3) 3 (ANZ) 14 (6.6; 3.8 to 11.0) 10 (5.8; 3.0 to 10.8) 
Pulmonary embolism 9 (2.3; 1.2 to 4.6) 3 (ANZ) 9 (4.2; 2.1 to 8.1) 0 (0; 0.0 to 2.7) 
Chronic renal disease 13 (3.4; 1.9 to 5.9) 3 (ANZ) 9 (4.2; 2.1 to 8.1) 4 (2.3; 0.8 to 6.3) 
Usual medications, No. (%; 95% CI) 
Inhaled beta-sympathomimetics 289 (74.9; 70.2 to 79.1) 1 (ANZ) 167 (77.7; 71.4 to 82.9) 122 (71.3; 63.9 to 77.9) 
Inhaled anticholinergics 49 (12.7; 9.7 to 16.6) 2 (ANZ) 35 (16.4; 11.8 to 22.2) 14 (8.2; 4.7 to 13.6) 
Inhaled corticosteroids 177 (46.0; 40.9 to 51.1) 2 (ANZ) 112 (52.3; 45.4 to 59.2) 65 (38.0; 30.8 to 45.8) 
Oral corticosteroids 52 (13.5; 10.4 to 17.5) 3 (ANZ) 37 (17.4; 12.7 to 23.3) 15 (8.8; 5.2 to 14.3) 
Leukotriene receptor antagonists 18 (4.7; 2.9 to 7.5) 3 (ANZ) 8 (3.8; 1.8 to 7.5) 10 (5.8; 3.0 to 10.8) 
Methylxanthines 11 (2.9; 1.5 to 5.2) 3 (ANZ) 3 (1.4; 0.4 to 4.4) 8 (4.7; 2.2 to 9.3) 
Home oxygen 4 (1.0; 0.3 to 2.8) 3 (ANZ) 3 (1.4; 0.4 to 4.4) 1 (0.6; 0.0 to 3.7) 
Arrival by ambulance, No. (%; 95% 
CI) 
115 (30.4; 25.9 to 35.4) 9 (4 ANZ, 
5 SEA) 
79 (37.3; 30.8 to 44.2) 36 (21.7; 15.8 to 28.9) 
IQR, interquartile range; ANZ, Australia and New Zealand; SEA, South East Asia and Hong Kong
Table 2. Clinical Features and Investigations 
Variable Result (N=387) 
Missing 
data 
Duration of symptoms (days), median (IQR) 2 (1-4) 8 
Ability to speak, No. (%; 95% CI) 72 
Unable 12 (3.8; 2.1 to 6.7) 
Phrases 47 (14.9; 11.3 to 19.5) 
Sentences 118 (37.5; 32.1 to 43.1) 
Normal 138 (43.8; 38.3 to 49.5) 
Pulse rate (beats per minute), median (IQR) 99 (86-110) 7 
Pulse rate ≥ 120, No. (%; 95% CI) 53 (13.9; 10.7 to 17.9) 
Respiratory rate (breaths per minute), median (IQR) 22 (20-25) 11 
Respiratory rate ≥ 30, No. (%; 95% CI) 41 (10.9; 8.0 to 14.6) 
Systolic blood pressure (mmHg), median (IQR) 133 (120-147) 13 
Systolic blood pressure < 100mmHg, No. (%) 10 (2.7; 1.4 to 5.0) 
Temperature < 35oC or ≥ 38.5oC, No. (%; 95% CI) 21 (5.6; 3.6 to 8.6) 13 
Oxygen saturation on room air (%), No. (%; 95% CI) 40a 
<94% 59 (17.0; 13.3 to 21.5) 
<90% 21 (6.1; 3.9 to 9.3) 
Findings on auscultation, No. (%; 95% CI) 9 
Wheeze 216 (57.1; 52.0 to 61.2) 
Widespread rhonchi 72 (19.1; 15.3 to 23.5) 
Normal 63 (16.7; 13.1 to 20.9) 
Local rhonchi/ bronchial breathing 16 (4.2; 2.5 to 6.9) 
Basal rales 9 (2.4; 1.2 to 4.6) 
Widespread rales 2 (0.5; 0.1 to 2.1) 
White cell count > 15.0 x 109/L, No. (%; 95% CI) 31 (13.3; 9.4 to 18.5) 154 
Blood gas taken (venous or arterial), No. (%; 95% CI) 91 (23.5; 19.34 to 28.1) 0 
pCO2 > 50mmHg 4 (1.0; 0.3 to 2.8) 
pH < 7.3 8 (2.1; 1.0 to 4.2) 
Imaging, No. (%; 95% CI) 1 
Chest X-ray 272 (70.5; 65.6 to 74.9) 
Ventilation perfusion scan or CTPA 1 (0.3; 0.0 to 1.7) 
Lung ultrasound 1 (0.3; 0.0 to 1.7) 
CTPA, computed tomography pulmonary angiography 
a Of these 40 patients, 36 were on supplemental oxygen at initial oxygen saturation reading. 
Table 3. Treatment and Outcome 
Variable Total population (N=387) 
Missing 
data 
ANZ (n=216) SEA (n=171) 
Oxygen therapy 
Initial oxygen therapy, No. (%; 
95% CI) 
0 
None 274 (70.8; 66.0 to 75.2) 153 (70.8; 64.2 to 76.7) 121 (70.8; 63.2 to 77.3) 
Face mask 46 (11.9; 8.9 to 15.6) 39 (18.1; 13.3 to 24.0) 7 (4.1; 1.8 to 8.6) 
Venturi-type system 4 (1.0; 0.3 to 2.8) 2 (0.9; 0.2 to 3.7) 2 (1.2; 0.2 to 4.6) 
Non-rebreather mask 7 (1.8; 0.8 to 3.9) 5 (2.3; 0.9 to 0.6) 2 (1.2; 0.2 to 4.6) 
Low flow nasal cannula 25 (6.5; 4.3 to 9.5) 14 (6.5; 3.7 to 10.9) 11 (6.4; 3.4 to 11.5) 
Non-invasive ventilation 1 (0.3; 0.0 to 1.7) 1 (0.5; 0.0 to 3.0) 0 (0.0 to 2.7) 
Oxygen given but mode 
unknown 
30 (7.8; 5.4 to 1.1) 2 (0.9; 0.2 to 3.7) 28 (16.4; 11.3 to 23.0) 
Oxygenation mode used at any 
time in ED, No. (%; 95% CI) 
0 
High-flow nasal cannula 4 (1.0; 0.3 to 2.8) 1 (0.5; 0.0 to 3.0) 3 (1.8; 0.5 to 5.4) 
Non-invasive ventilation 8 (2.1; 1.0 to 4.2) 6 (2.8; 1.1 to 6.2) 2 (1.2; 0.2 to 4.6) 
Mechanical ventilation 0 (0; 0.0 to 1.2) 0 (0; 0.0 to 2.2) 0 (0; 0.0 to 2.8) 
Pharmacotherapy, No. (%; 95% 
CI) 
Inhaled beta sympathomimetic 339 (87.8; 84.0 to 90.8) 1 (ANZ) 183 (85.1; 79.5 to 89.5) 156 (91.2; 85.7 to 94.8) 
Inhaled anticholinergic agent 215 (55.8; 50.7 to 60.9) 2 (ANZ) 124 (57.9; 51.0 to 64.6) 91 (53.2; 45.5 to 60.8) 
Inhaled bronchodilator (beta-
sympathomimetic or 
anticholinergic) 
340 (87.8; 84.1 to 90.9) 0 184 (85.2; 79.6 to 89.5) 156 (91.2; 85.7 to 94.8) 
Oral corticosteroid 208 (53.9; 48.8 to 58.9) 1 (ANZ) 124 (57.7; 50.8 to 64.3) 84 (49.1; 41.4 to 56.8) 
Intravenous corticosteroid 77 (20.1; 16.2 to 24.5) 3 (ANZ) 43 (20.2; 15.1 to 26.3) 34 (19.9; 14.3 to 26.8) 
Systemic corticosteroid (Oral or 
IV) 
268 (69.4; 64.5 to 73.9) 1 (ANZ) 152 (70.7; 64.1 to 76.6) 116 (67.8; 60.2 to 74.7) 
Antibiotic 89 (23.2; 19.1 to 27.8) 3 (ANZ) 65 (30.5; 24.5 to 37.3) 24 (14.0; 9.4 to 20.4) 
Both inhaled bronchodilators and 
systemic corticosteroids 
258 (66.8; 61.9 to 71.5) 1 (ANZ) 144 (67.0; 60.2 to 73.1) 114 (66.7; 59.0 to 73.6) 
Outcome 
Disposition, No. (%; 95% CI) 0 
Home (including via an ED 
observation unit) 
253 (65.4; 60.4 to 70.1) 130 (60.2; 53.3 to 66.7) 123 (71.9; 64.8 to 78.1) 
Inpatient ward (excluding ICU) 122 (31.5; 27.0 to 36.4) 76 (35.2; 28.9 to 42.0) 46 (26.9; 20.6 to 34.3) 
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ICU 11 (2.8; 1.5 to 5.2) 9 (4.2; 2.1 to 8.0) 2 (1.2; 0.2 to 4.6) 
Transfer 1 (0.3; 0.0 to 1.7) 1 (0.5; 0.0 to 3.0) 0 (0; 0.0 to 2.7) 
Death in ED 0 (0; 0.0 to 1.2) 0 (0; 0.0 to 2.2) 0 (0; 0.0 to 2.7) 
In-hospital mortality 0 (0; 0.0 to 1.2) 0 (0; 0.0 to 2.2) 0 (0; 0.0 to 2.7) 
Length of stay for admitted 
patients (days), median (IQR) 
4 (3-6) 1 (SEA) 4 (3-5) 4 (3-6) 
IQR, interquartile range; ANZ, Australia and New Zealand; SEA, South East Asia and Hong Kong 
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